全球健康还是全球财富？ - Suppr

Global health or global wealth?

作者信息

Rezaie Rahim, Singer Peter A

机构信息

McLaughlin-Rotman Centre for Global Health, University Health Network and University of Toronto, Toronto, Ontario, Canada.

出版信息

Nat Biotechnol. 2010 Sep;28(9):907-9. doi: 10.1038/nbt0910-907.

DOI:10.1038/nbt0910-907

PMID:20829824

Abstract

摘要

相似文献

Global health or global wealth?

Nat Biotechnol. 2010 Sep;28(9):907-9. doi: 10.1038/nbt0910-907.

The National Institutes of Health Small Business Innovation Research (SBIR) Program: opportunities for orphan drug development.

Prog Clin Biol Res. 1985;197:25-30.

Perspectives. Orphan Drug Act stumps lawmakers.

Faulkner Grays Med Health. 1990 Jun 25;44(25):suppl 4 p..

The economics of orphan drug policy in the US. Can the legislation be improved?

Pharmacoeconomics. 1995 Nov;8(5):374-84. doi: 10.2165/00019053-199508050-00002.

Adoption agent.

Minn Med. 2005 Mar;88(3):8-9.

Introduction-Current activities and future goals of orphan disease agencies.

Prog Clin Biol Res. 1985;197:3-6.

Drug legislation. Drug companies divided.

Nature. 1990 May 3;345(6270):6. doi: 10.1038/345006a0.

Improving access to medicines in poor countries: the role of universities.

PLoS Med. 2006 Apr;3(6):e136. doi: 10.1371/journal.pmed.0030136.

Pharmaceuticals, patents, publicity...and philanthropy?

Lancet. 2009 Feb 28;373(9665):693. doi: 10.1016/S0140-6736(09)60410-4.

Drug development. Orphan drug windfalls?

Nature. 1992 Jan 30;355(6359):381. doi: 10.1038/355381b0.

引用本文的文献

Towards a sustainable rare disease and orphan drug ecosystem in Saudi Arabia: policy insights from a multi-stakeholder workshop.

Front Pharmacol. 2025 May 1;16:1583477. doi: 10.3389/fphar.2025.1583477. eCollection 2025.

Vaccines (Basel). 2023 Jan 2;11(1):110. doi: 10.3390/vaccines11010110.

Obstacles and opportunities in Chinese pharmaceutical innovation.

Global Health. 2017 Mar 24;13(1):21. doi: 10.1186/s12992-017-0244-6.

World health dilemmas: Orphan and rare diseases, orphan drugs and orphan patients.

World J Methodol. 2014 Sep 26;4(3):163-88. doi: 10.5662/wjm.v4.i3.163.

Emergence of biopharmaceutical innovators in China, India, Brazil, and South Africa as global competitors and collaborators.

Health Res Policy Syst. 2012 Jun 6;10:18. doi: 10.1186/1478-4505-10-18.

Indian vaccine innovation: the case of Shantha Biotechnics.

Global Health. 2011 Apr 20;7:9. doi: 10.1186/1744-8603-7-9.

本文引用的文献

A business plan to help the 'global South' in its fight against neglected diseases.

Health Aff (Millwood). 2009 Nov-Dec;28(6):1760-73. doi: 10.1377/hlthaff.28.6.1760.

Progress in public-private partnerships to fight neglected diseases.

Health Aff (Millwood). 2009 Nov-Dec;28(6):1745-9. doi: 10.1377/hlthaff.28.6.1745.

Small but tenacious: South Africa's health biotech sector.

Nat Biotechnol. 2009 May;27(5):427-45. doi: 10.1038/nbt0509-427.

Eliminating neglected diseases in poor countries: a conversation with Andrew Witty. Interview by Susan Dentzer.

Health Aff (Millwood). 2009 May-Jun;28(3):w411-6. doi: 10.1377/hlthaff.28.3.w411. Epub 2009 Mar 19.

The Indian and Chinese health biotechnology industries: potential champions of global health?

Health Aff (Millwood). 2008 Jul-Aug;27(4):1029-41. doi: 10.1377/hlthaff.27.4.1029.

Brazilian health biotech--fostering crosstalk between public and private sectors.

Nat Biotechnol. 2008 Jun;26(6):627-44. doi: 10.1038/nbt0608-627.

Chinese health biotech and the billion-patient market.

Nat Biotechnol. 2008 Jan;26(1):37-53. doi: 10.1038/nbt0108-37.

Grand challenges in chronic non-communicable diseases.

Nature. 2007 Nov 22;450(7169):494-6. doi: 10.1038/450494a.

India's health biotech sector at a crossroads.

Nat Biotechnol. 2007 Apr;25(4):403-17. doi: 10.1038/nbt0407-403.

Developing drugs for developing countries.

Health Aff (Millwood). 2006 Mar-Apr;25(2):313-24. doi: 10.1377/hlthaff.25.2.313.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Global health or global wealth?

Nat Biotechnol. 2010 Sep;28(9):907-9. doi: 10.1038/nbt0910-907.

The National Institutes of Health Small Business Innovation Research (SBIR) Program: opportunities for orphan drug development.

Prog Clin Biol Res. 1985;197:25-30.

Perspectives. Orphan Drug Act stumps lawmakers.

Faulkner Grays Med Health. 1990 Jun 25;44(25):suppl 4 p..

The economics of orphan drug policy in the US. Can the legislation be improved?

Pharmacoeconomics. 1995 Nov;8(5):374-84. doi: 10.2165/00019053-199508050-00002.

Adoption agent.

Minn Med. 2005 Mar;88(3):8-9.

Introduction-Current activities and future goals of orphan disease agencies.

Prog Clin Biol Res. 1985;197:3-6.

Drug legislation. Drug companies divided.

Nature. 1990 May 3;345(6270):6. doi: 10.1038/345006a0.

Improving access to medicines in poor countries: the role of universities.

PLoS Med. 2006 Apr;3(6):e136. doi: 10.1371/journal.pmed.0030136.

Pharmaceuticals, patents, publicity...and philanthropy?

Lancet. 2009 Feb 28;373(9665):693. doi: 10.1016/S0140-6736(09)60410-4.

Drug development. Orphan drug windfalls?

Nature. 1992 Jan 30;355(6359):381. doi: 10.1038/355381b0.

引用本文的文献

Towards a sustainable rare disease and orphan drug ecosystem in Saudi Arabia: policy insights from a multi-stakeholder workshop.

Front Pharmacol. 2025 May 1;16:1583477. doi: 10.3389/fphar.2025.1583477. eCollection 2025.

Vaccines (Basel). 2023 Jan 2;11(1):110. doi: 10.3390/vaccines11010110.

Obstacles and opportunities in Chinese pharmaceutical innovation.

Global Health. 2017 Mar 24;13(1):21. doi: 10.1186/s12992-017-0244-6.

World health dilemmas: Orphan and rare diseases, orphan drugs and orphan patients.

World J Methodol. 2014 Sep 26;4(3):163-88. doi: 10.5662/wjm.v4.i3.163.

Emergence of biopharmaceutical innovators in China, India, Brazil, and South Africa as global competitors and collaborators.

Health Res Policy Syst. 2012 Jun 6;10:18. doi: 10.1186/1478-4505-10-18.

Indian vaccine innovation: the case of Shantha Biotechnics.

Global Health. 2011 Apr 20;7:9. doi: 10.1186/1744-8603-7-9.

本文引用的文献

A business plan to help the 'global South' in its fight against neglected diseases.

Health Aff (Millwood). 2009 Nov-Dec;28(6):1760-73. doi: 10.1377/hlthaff.28.6.1760.

Progress in public-private partnerships to fight neglected diseases.

Health Aff (Millwood). 2009 Nov-Dec;28(6):1745-9. doi: 10.1377/hlthaff.28.6.1745.

Small but tenacious: South Africa's health biotech sector.

Nat Biotechnol. 2009 May;27(5):427-45. doi: 10.1038/nbt0509-427.

Eliminating neglected diseases in poor countries: a conversation with Andrew Witty. Interview by Susan Dentzer.

Health Aff (Millwood). 2009 May-Jun;28(3):w411-6. doi: 10.1377/hlthaff.28.3.w411. Epub 2009 Mar 19.

The Indian and Chinese health biotechnology industries: potential champions of global health?

Health Aff (Millwood). 2008 Jul-Aug;27(4):1029-41. doi: 10.1377/hlthaff.27.4.1029.

Brazilian health biotech--fostering crosstalk between public and private sectors.

Nat Biotechnol. 2008 Jun;26(6):627-44. doi: 10.1038/nbt0608-627.

Chinese health biotech and the billion-patient market.

Nat Biotechnol. 2008 Jan;26(1):37-53. doi: 10.1038/nbt0108-37.

Grand challenges in chronic non-communicable diseases.

Nature. 2007 Nov 22;450(7169):494-6. doi: 10.1038/450494a.

India's health biotech sector at a crossroads.

Nat Biotechnol. 2007 Apr;25(4):403-17. doi: 10.1038/nbt0407-403.

Developing drugs for developing countries.

Health Aff (Millwood). 2006 Mar-Apr;25(2):313-24. doi: 10.1377/hlthaff.25.2.313.

Global health or global wealth?

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Global health or global wealth?

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献